Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 16/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28963628 | 0.92 | ATM (0.48) | FYNATMRAD52 | |
| SCHEMBL23535596 | 0.88 | RAB9A (0.53) | FYNATMRAD52RAB9AGABRA5 | |
| SCHEMBL23535507 | 0.88 | FYN (0.48) | FYNMAPT | |
| SCHEMBL23535524 | 0.88 | FYN (0.61) | FYNRAD52 | |
| SCHEMBL23535503 | 0.87 | FYN (0.53) | FYNATMRAD52 | |
| SCHEMBL28963626 | 0.86 | FYN (0.48) | FYNATMRAD52 | |
| SCHEMBL23535481 | 0.83 | CACNA1B (0.52) | ATMMAPT | |
| SCHEMBL23535506 | 0.81 | CYP3A4 (0.59) | FYN | |
| SCHEMBL23535532 | 0.81 | CD274 (0.66) | — | |
| SCHEMBL23535588 | 0.80 | LDHA (0.53) | ATMMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115768757-A | CD206 modulators and uses and methods of making thereof | 美利坚合众国,由健康及人类服务部部长代表 | 2023-03-07 | — | — | CN | disclosed |
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | US HEALTH (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4077297-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | CD209, MSR1, ARG1 | FYN 1874/4885ATM 3092/4885RAD52 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.